The EU’s upcoming pharma strategy offers an important opportunity for changes that could bolster Europe’s supply chain and improve stakeholder co-ordination, according to Medicines for Europe. Five key issues that should be addressed by the EU Commission have been set out by the off-patent industry association an open letter to European Commission president Ursula von der Leyen.
The five areas cited by the association are: supply security; sustainable and accessible pharmaceutical budgets; making medicines regulation fit for...